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Myoclonus-dystonia (M-D) is a rare movement disorder characterized by a combination of non-epileptic myoclonic jerks and dystonia.
SGCEmutations represent a major cause for familial M-D being responsible for 30%–50% of cases. After excluding SGCEmutations, we
identified through a combination of linkage analysis and whole-exome sequencing KCTD17 c.434 G>A p.(Arg145His) as the only segre-
gating variant in a dominant British pedigree with seven subjects affected by M-D. A subsequent screening in a cohort of M-D cases
without mutations in SGCE revealed the same KCTD17 variant in a German family. The clinical presentation of the KCTD17-mutated
cases was distinct from the phenotype usually observed in M-D due to SGCE mutations. All cases initially presented with mild myoc-
lonus affecting the upper limbs. Dystonia showed a progressive course, with increasing severity of symptoms and spreading from the
cranio-cervical region to other sites. KCTD17 is abundantly expressed in all brain regions with the highest expression in the putamen.
Weighted gene co-expression network analysis, based on mRNA expression profile of brain samples from neuropathologically healthy
individuals, showed that KCTD17 is part of a putamen gene network, which is significantly enriched for dystonia genes. Functional
annotation of the network showed an over-representation of genes involved in post-synaptic dopaminergic transmission. Functional
studies in mutation bearing fibroblasts demonstrated abnormalities in endoplasmic reticulum-dependent calcium signaling. In conclu-
sion, we demonstrate that the KCTD17 c.434 G>A p.(Arg145His) mutation causes autosomal dominant M-D. Further functional studies
are warranted to further characterize the nature of KCTD17 contribution to the molecular pathogenesis of M-D.Dystonias are a clinically and genetically heterogeneous
group of non-neurodegenerative movement disorders,
mainly characterized by involuntary muscle contractions
leading to abnormal postures or movements of body seg-
ments.1 Mutations in a growing number of genes (recently
reviewed by our group)2 are responsible for Mendelian
forms of dystonia. The identification of these genes al-
lowed the recognition of different cellular pathways
involved in the molecular pathogenesis of dystonia,
including perturbed synaptic transmission and plasticity,
abnormal transcription and cell-cycle regulation, and
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938 The American Journal of Human Genetics 96, 938–947, June 4, 2The association with additionalmovement disorders iden-
tifies a sub-group of dystonias, defined as combined dysto-
nias.4 Myoclonus-dystonia (M-D [MIM 159900]), one of the
combined dystonia syndromes, is a very rare condition with
a suggested prevalence of about two per million in Europe.5
M-D is clinically characterized by a variable combination of
non-epileptic myoclonic jerks, mainly affecting the upper
body, and mild to moderate dystonia, usually in the form of
cervical dystonia or writer’s cramp.6 There is often a dramatic
improvementofmyoclonusafter alcoholconsumption.7Psy-
chiatric co-morbidities (e.g., depression, anxiety, and obses-
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Figure 1. Family Trees, Linkage Analysis, and KCTD17 Mutation Analysis
(A and B) Pedigree of the British (A) and German (B) families with the KCTD17 c.434 G>A p.(Arg145His) mutation. Open symbols indi-
cate unaffected family members, and solid black symbols indicate affected members. Individuals marked with an asterisk were clinically
examined. The following abbreviations are used: WT, homozygous wild-type alleles; and M, heterozygous mutation carrier.
(C) LOD score plot for genome-wide linkage analysis in the British index pedigree showing a single linkage peak on chromosome 22q13
with amaximum LOD score of 2.4. An autosomal dominantmodel was specified with an estimated allele frequency of 0.00001 and 90%
penetrance.
(D) Sanger sequencing confirmation of the KCTD17 c.434G>A p.(Arg145His) mutation.
(E) Multiple-sequence alignment showing complete conservation of protein sequence across species and human paralogs (KCTD2 and
KCTD5) in the region of exon 4 of KCTD17, in which the disease-segregating mutation p.(Arg145His) was found.Mutations in SCGE [MIM 604149], coding for ε-sarcogly-
can, represent a major cause of inherited autosomal domi-
nant M-D.9 SGCE mutations are detected in 30%–50% of
familial M-D cases, suggesting genetic heterogeneity and
the existence of mutations in other genes responsible for
this condition.10–14
We used a combination of genome-wide linkage anal-
ysis and whole-exome sequencing to investigate a previ-
ously unpublished dominant British pedigree (shown in
Figure 1A) with multiple individuals affected with M-D,
in which SCGE mutations (both point mutations and
copy number variants) had been excluded.
Out of 19 living family members from the index family,
14 were clinically assessed. Assessment included a detailed
medical interview and a full-videotaped neurological ex-
amination, with focus on movement disorders. All videos
were reviewed by two experts in movement disorders,
blinded to disease status.
The proband (III-2) developed involuntary jerky move-
ments of her arms during childhood. In her late forties
she developed constant head jerks and head deviation to
the left. In her sixties her speech became involved. On ex-The Amamination at the age of 69 she had spasmodic dysphonia,
facial myoclonus, blepharospasm, left torticollis, and
frequent irregular dystonic head jerks. There was dystonic
hand posturing and low amplitude brief myoclonus.
When she walked she presented trunk and bilateral foot
dystonia (Movie S1, section 1).
Six other family members displayed signs of dystonia
and/or myoclonus, and were accordingly categorized as
affected (Table 1). Age of onset of movement disorder
symptoms ranged from 5 to 20 years. All affected family
members initially presented with jerks or a jerky tremor,
with mild dystonic features presenting later in life. All
cases fulfilled the currently proposed clinical criteria for a
definite diagnosis of M-D,15 except individual IV-3, who
upon examination displayed isolated cervical dystonia,
although she reported intermittent jerky arm tremor.
Myoclonus involved predominantly the arms (Movie S1,
section 2). Dystonia predominantly affected the cranio-
cervical region and upper limbs. Older individuals (>60
years; III-2 and III-5) were more severely affected and also
showed laryngeal involvement. None of the affected sub-
jects reported improvement of symptoms with alcohol.erican Journal of Human Genetics 96, 938–947, June 4, 2015 939
Table 1. Clinical Features of Cases Harboring the KCTD17 c.434 G>A p.(Arg145His) Mutation
Subject III-2 III-5 IV-2 IV-3 IV-14 V-1 V-3 II.2 (Germany)
Sex F F M F M F M M
Age at last
examination (y)
70 65 46 44 35 20 19 62
Age at onset (y) 10 6 10 20 10 5 5 10
Presenting
symptoms
Jerks; Arms Jerks; Arms Jerks; Arms Jerky tremor;
Arms
Jerky tremor;
Arms
Jerks; Arms Jerks; Arms Jerks, Arms
Dystonic
features
Yes Yes Yes Yes Yes Yes No Yes
Involved areas Cranial, Cervical,
Brachial, Truncal,
Crural
Cranial,
Cervical,
Brachial
Brachial Cervical Cervical,
Brachial
Brachial NA Cranial, Cervical,
Brachial, Truncal
Myoclonus Yes Yes Yes No Yes Yes Yes Yes
Involved areas Cranial, Cervical,
Brachial
Cranial,
Brachial
Brachial NA Cranial,
Brachial
Brachial Cervical,
Brachial
BrachialSubject IV-3 had anxiety and social phobia and subject IV-
14 had obsessive traits and suffered from depression. No
other individuals presented with psychiatric symptoms.
Case IV-12 had strabismus and benign congenital
nystagmus, but no signs of M-D. The remaining individ-
uals were asymptomatic and had an entirely normal neuro-
logical examination.
Samples were collected with the written consent of par-
ticipants and formal ethical approval by the relevant
research ethics committee (UCLH Project ID number
06/N076). DNA of 13 family members and 4 spouses was
extracted from blood lymphocytes.
A genome-wide linkage analysis was subsequently per-
formed in 7 affected individuals (III-2, III-5, IV-1, IV-3,
IV-14, V-1, and V-3), 5 unaffected (III-4, IV-6, IV-8, IV-12,
and V-4) and 4 spouses using the HumanCytoSNP-12
DNA Analysis BeadChip Kit (Illumina). The unaffected
subject V-2 was not included as she was too young (17
when last examined) to exclude or confirm disease status.
Genome-widemultipoint parametric linkage analysis for
an autosomal dominant model (estimated allele frequency
0.00001 and 90% penetrance) and haplotype reconstruc-
tion were performed with Simwalk2,16 using 24,000 infor-
mative single nucleotide polymorphisms (SNPs), equally
spaced 0.1cM apart as described before.17
One single locus with a LOD score > 2 was identified on
chromosome 22q13 (LOD score 2.4, the maximal expected
value given the pedigree size; see Figure 1C).
Fine mapping identified a segregating haplotype delimi-
tated by SNP markers rs926543 and rs3213584 and
spanning 6.7 Mb (chr22:36989327–43716324; UCSC
hg19 Genome Build), which contained 132 protein-coding
genes. In addition, five other regions presented with unin-
formative multipoint LOD scores, ranging from 0.9 to
þ0.14, but haplotype analysis excluded segregation of
these regions with the disease.
We subsequently performed whole-exome sequencing
in the two most distantly related affected individuals (V-3940 The American Journal of Human Genetics 96, 938–947, June 4, 2and IV-14). In short, paired-end sequence reads (TruSeq
SBS chemistry sequenced on the Illumina HiSeq 2000)
were aligned with Novoalign against the reference human
genome (UCSC hg19). Duplicate read removal, format con-
version, and indexing were performed with Picard. The
Genome Analysis Toolkit (GATK) was used to recalibrate
base quality scores, perform local realignments around
possible indels, and to call and filter the variants. Annotated
variant files were generated using ANNOVAR18 and in-
cluded a comparison to publicly available databases of
sequence variations (dbSNP version 129, 1000 Genomes
project, NHLBI Exome Variant Server, and Complete Geno-
mics 69). In silico prediction of pathogenicity was assessed
using SIFT,19 PolyPhen2,20 MutationTaster,21 Provean,22
and CADD.23 Conservation of nucleotides involved by var-
iants was scored using Genomic Evolutionary Rate Profiling
(GERP).24 Interspecies alignment of protein sequences was
generated using ClustalW2.25
In total, 83,572,847 (V-3) and 81,527,162 (IV-14) unique
reads were generated. According to the Consensus Coding
Sequences hg19 definition of the ‘‘TruSeq exome,’’ the
average read depth of both exomes was >70, >95% of
the target bases were covered at a read depth of 23,
and > 90% at a depth of 103. A total of 22,857 (V-3) and
22,946 (IV-14) exonic/splicing variants were detected. We
filtered out all synonymous changes and those not shared
by the two affected individuals. Then, under the assump-
tion that the mutation causing this rare autosomal domi-
nant disease is extremely rare and not present in the
general population, we also excluded variants that are pre-
sent in the databases of sequence variations listed above.
Furthermore, we excluded variants found in our own in-
house exomes (n ¼ 200) from individuals with unrelated
diseases.
After applying filtering criteria, we were left with only 4
novel missense variants shared by the two affected individ-
uals (see Table S1): c.10976 C>T p.(Ser3659Phe) in FLG (fi-
laggrin; RefSeq NM_002016.1), c.1055 T>Gp.(Phe352Cys)015
in OBSCN (obscurin; RefSeq NM_052843.3), c.1076 A>C
p.(Lys359Thr) in LRRC6 (leucine rich repeat containing
6; RefSeq NM_012472.4) and c.434 G>A p.(Arg145His)
in KCTD17 (potassium channel tetramerization domain
containing 17; RefSeq NM_001282684.1). Of these vari-
ants, only the missense change in KCTD17 was located
within the linked chromosomal locus on chromosome
22q. We did not detect any shared rare copy-number vari-
ants in exome sequencing data using the Exome depth
algorithm.26
Sanger sequencing in all available family members
confirmed perfect co-segregation of the KCTD17 variant
with the disease-phenotype, being the nucleotide change
present in all affected individuals and absent in all unaf-
fected (including subject V-2, initially excluded from the
linkage analysis). The variant is absent in over 3,700 indi-
viduals of European origin without movement disorders,
who were exome sequenced by the UCL-exomes con-
sortium, and in a further >61,000 individuals listed in
the Exome Aggregation Consortium database (last accessed
in March 2015).
Although the KCTD17 p.(Arg145His) substitution falls
in a functionally uncharacterized portion of the protein,
it lies in an extremely conserved amino acid motif, not
only completely conserved down to invertebrate species,
but also identical in the KCTD17 human paralogs KCTD2
and KCTD5 (Figure 1E). All in silico tools consistently pre-
dicted a deleterious effect of the substitution (Table S1).
We subsequently sequenced the 9 coding exons of
KCTD17 (NM_001282684.1; primers available in Table
S2) in a further 87 unrelated probands with familial M-D
of British, German, and Italian origin. None of the cases
harbored mutations in SGCE. Mutational screening of
KCTD17 exon 4 (containing the c.434 G>A mutation)
was performed in a further 358 sporadic M-D cases without
mutations in SCGE.
This analysis revealed the presence of the same KCTD17
mutation, c.434 G>A p.(Arg145His), in the index case of a
German family with autosomal dominantM-D (Figure 1B).
No further likely pathogenic mutations were identified.
The clinical presentation of this case closely resembled
that of III-2 and III-5, the older affected subjects from the
British family. He reported arm jerks and difficulty writing,
starting in childhood. Right torticollis and a jerky head
tremor appeared around age 40, becoming progressively
debilitating. There was no response to alcohol or psychiat-
ric comorbidities. He underwent surgery for bilateral pal-
lidal deep brain stimulation at age 58, which resulted in
marked improvement of cervical dystonia and myoclonus
of the upper limbs. Clinical examination at age 62 showed
generalized dystonia, with prominent cranio-cervical in-
volvement, andmyoclonic jerks involving the upper limbs
(Movie S1, section 3). His father was also affected with a
movement disorder, presenting with perioral dyskinesia
in his forties. The proband’s brother had M-D, with similar
clinical features, including generalized jerks, cervical
dystonia, and dysarthria. Unfortunately, DNA samples ofThe Amthe deceased father and brother were not available for
segregation analysis. The 25-year-old proband’s only son,
who had no signs upon examination, refused genetic
testing.
Haplotype comparison between the two pedigrees with
KCTD17 c.434 G>A p.(Arg145His) was performed with
SNP markers located 0.5 Mb up- and downstream of the
mutation. This analysis showed that different alleles are
located at markers rs5756477 and rs228924, delimitating
a small region of ~100 Kb of a possibly shared haplotype
(Table S3). A further analysis with a highly polymorphic
microsatellite, located only 1.4 Kb upstream of the 50 end
of KCTD17, revealed that the two pedigrees have different
alleles, possibly suggesting the absence of a shared ances-
tral haplotype and that the variant might have arisen inde-
pendently in the two pedigrees. Of relevance, the absence
of a shared haplotype between the two families would
make unlikely that the KCTD17 c.434 G>A p.(Arg145His)
mutation is in linkage disequilibrium with the actual caus-
ative mutation but not itself pathogenic.
We explored the regional distribution of KCTD17 expres-
sion in the normal adult human brain. As previously
described, we used microarray data (Affymetrix Exon 1.0
ST) from human post-mortem brain tissue collected by
the UK Human Brain Expression Consortium (UKBEC).27
KCTD17 mRNA expression throughout the course of
human brain development was assessed using the data
available in the Human Brain Transcriptome (HBT) data-
base.28,29 KCTD17 mRNA expression was high across all
brain regions, but it was highest in the putamen followed
by the thalamus (Figure 2A). These findings are consistent
with the data available in the HBT database, showing
increasing KCTD17 brain mRNA levels in the striatum
and the thalamus from early midfetal development to
adolescence (Figure 2B). In light of the current view of
the neuroanatomical bases of dystonia, which is thought
to be a network disorder of the basal ganglia connec-
tions,30,31 this pattern of expression is highly relevant
and supports the pathogenic role of KCTD17 in the patho-
genesis of M-D.
KCTD17 encodes for a member of a recently identified
family of 26 closely related and highly conserved proteins,
the potassium channel tetramerization domain (KCTD)-
containing proteins. KCTD proteins are characterized by
the presence of a N-terminal bric-a-brack, tram-track,
broad complex/poxvirus zinc finger (BTB/POZ) domain,
homologous to the cytoplasmic domain T1 of voltage-
gated potassium channels.32 The BTB/POZ domain is
known to permit protein-protein interactions, either pro-
moting self-oligomerization or facilitating interaction
with other biological partners.33 KCTDs are small soluble
proteins, which are not predicted by their structure to
form transmembrane domains. Despite the homology re-
flected in their names, a direct interaction with potassium
channels has not been shown for most members of the
family and was explicitly excluded for KCTD5, a paralog
85% identical to KCTD17.34erican Journal of Human Genetics 96, 938–947, June 4, 2015 941
Figure 2. Summary of Brain Regional mRNA Expression Data
(A) Box plot of mRNA expression levels for KCTD17 in ten adult brain regions, based on exon array experiments and plotted on a log2
scale (y axis). This dataset was generated using Affymetrix Exon 1.0 ST Arrays and brain and CNS tissue originating from 134 control
individuals, collected by the Medical Research Council (MRC) Sudden Death Brain and Tissue Bank, and the Sun Health Research Insti-
tute (SHRI), an affiliate of Sun Health Corporation, USA.27 The plot shows significant variation in KCTD17 transcript expression across
the ten CNS regions analyzed: putamen (PUTM), frontal cortex (FCTX), temporal cortex (TCTX), hippocampus (HIPP), substantia nigra
(SNIG), medulla (specifically inferior olivary nucleus, MEDU), intralobular white matter (WHMT), thalamus (THAL), and cerebellar cor-
tex (CRBL). ‘‘N’’ indicates the number of brain samples analyzed to generate the results for each CNS region. KCT17 expression is higher
in the putamen, followed by the thalamus. Whiskers extend from the box to 1.53 the interquartile range.
(B) Graph to showmRNA expression levels for KCTD17 in 6 brain regions during the course of human brain development, based on exon
array experiments and plotted on a log2 scale (y axis).28,29 The brain regions analyzed are the striatum (STR), amygdala (AMY), neocortex
(NCX), hippocampus (HIP), mediodorsal nucleus of the thalamus (MD), and cerebellar cortex (CBC). This shows increasing expression of
KCTD17 mRNA during human brain development, particularly in the striatum and thalamus, from the early midfetal period to
adolescence.KCTD proteins, despite the high level of sequence simi-
larity, are involved in a surprisingly wide spectrum of cell
functions, including regulation of cellular proliferation,
gene transcription, cytosketelon organization, protein
degradation targeting via the ubiquitin-proteasome sys-
tem, and regulation of G protein-coupled receptors.35
Several members of the KCTD family have a primary role
in the central nervous system36,37 and a growing number
of neurological diseases have been linked to mutations in
KCTD genes. KCTD7 [MIM 611725] mutations cause reces-
sive progressive myoclonic epilepsy.38–40 Copy-number
variants in KCTD13 [MIM 608947] have been associated
with size of the head, autism disorder, and epilepsy.41
More recently, a homozygous missense mutation in
KCTD3 [MIM 613272] was identified as the likely cause
in a pedigree with severe psychomotor retardation, seizure,
and cerebellar hypoplasia.42
The precise cellular localization and function of the
KCTD17 protein are largely unknown. Recent work has
shown that KCTD17 contributes to the ubiquitin-protea-
some machinery, acting as an adaptor for the CUL3-RING
E3 ligase and targeting substrates for degradation through
polyubiquitinylation.43 Although most of the KCTD17-
CUL3 substrates are currently unknown, CUL3 has been942 The American Journal of Human Genetics 96, 938–947, June 4, 2implicated in the elaboration of dendrite branching and
neurite terminal morphogenesis in Drosophilamodels.44,45
Stably transfected SH-SY5 cells were generated by incor-
porating N- and C-terminally hemagglutinin (HA)-tagged
wild-type and mutant KCTD17 cDNAs. KCTD17 staining
with anti-HA primary monoclonal antibodies showed
that the protein is diffusely distributed in the cytosol
with fine reticular pattern and does not localize at the
plasma membrane (Figure S1). Co-staining with ER, Golgi
apparatus, mitochondria, and lysosomal markers failed to
show any co-localization with KCTD17 (data not shown).
We did not observe significant changes in subcellular local-
ization of mutant versus wild-type KCTD17, indicating
that the amino acid substitution does not lead to cellular
mislocalization of the protein.
To gain further insight into the functional role of
KCTD17 and identify molecular pathways possibly dysre-
gulated by mutant KCTD17, weighted gene co-expression
network analysis (WGCNA) was performed based on the
UKBEC human brain mRNA expression data. In brief,
this systems biology analytic approach uses brain regional
whole-transcriptome gene expression data and establishes
the degree of gene neighborhood sharing, as defined on
the basis of co-expression relationships. This approach015
Figure 3. Network Representation of
the Putamen KCTD17-Containing Gene
Module
Array expression profiling of 788 brain
samples obtained from 101 neuropatho-
logically healthy individuals was per-
formed and used for weighted gene co-
expression network analysis (WGCNA).
The WGCNA network was constructed
for each brain region using a scale-free
topology, as previously described.47 A
dissimilarity matrix based on topological
overlap measure was used to identify
gene modules (i.e., densely intercon-
nected and co-expressed genes) through
a dynamic tree-cutting algorithm. Shown
are all genes in the putamen KCTD17-con-
taining module connected with a topo-
logical overlap measure exceeding 0.03.
The dystonia genes in the module
(KCDT17 and HPCA) and all the direct
connections of KCTD17, based on topo-
logical overlap values, are highlighted in
red. Larger circles represent themost inter-
connected genes in the module, including
KCTD17.allows to identify in an unsupervised and unbiased
manner modules of genes that are highly co-expressed
and co-regulated and therefore likely to be functionally
related.46 Microarray data on 19152 transcripts (corre-
sponding to 17247 genes), generated from 101 brains,
were used to create weighted modules of co-expressed
genes for each analyzed brain regions. A detailed descrip-
tion of the methods used to generate the dataset is avail-
able in the manuscript of Forabosco and colleagues.47
KCTD17, in common with other genes associated with
dystonia (e.g., ANO3 [MIM 610110] and GNAL [MIM
139312]), shows the highest expression in the putamen
and this brain structure has an established role in the path-
ogenesis of dystonia. We therefore focused the analysis on
the putamen module including KCTD17. This module
contains 179 transcripts (equating to 172 genes; Table S4;
see Figure 3 for a graphic representation of the module).
We first assessed whether the module was enriched for
genes linked to Mendelian forms of dystonia. We focused
the analysis on the nine genes known to be associated
with dystonia (TOR1A [MIM 605204], THAP1 [MIM
609520], SGCE, TUBB4A [MIM 602662], CIZ1 [MIM
611420], ANO3, GNAL, ATP1A3 [MIM 182350], PRKRA
[MIM 603424])2 and HPCA [MIM 142622], a gene recently
associated with autosomal recessive dystonia.48We did not
include in the analysis genes causing DOPA-responsive
dystonia (GCH1 [MIM#600225], TH [MIM#191290], and
SPR [MIM 182125]) as their established functional role in
nigrostriatal dopamine synthesis, together with the speci-
ficity of the clinical presentation, clearly identifies them
as a separate entity.The AmImportantly, the putamen KCTD17-module showed sig-
nificant clustering of dystonia genes (KCTD17 and HPCA;
Fisher’s exact test p ¼ 5 3 103), suggesting the relevance
of this gene network to the molecular pathogenesis of
dystonia. The module was poorly preserved across other
brain regions, indicating its specificity to the putamen
(Figure S2). The brain regional specificity of this module
might suggest why mutations in KCTD17 and HPCAman-
ifest purely as a dysfunction of the basal ganglia (i.e., dys-
tonia), in spite of the ubiquitous expression in the human
brain.
To infer the biological and functional relevance of the
putamen KCTD17 gene network, we then carried out func-
tional annotation enrichment analysis using the online
tool g:Profiler.49 This analysis allowed the identification
of over-represented genes assigned to specific Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways,
namely ‘‘Circadian entrainment’’ (KEGG:04713; p ¼
5.13 3 103) and ‘‘Dopaminergic synapse’’ (KEGG:04728;
p ¼ 2.71 3 102). This suggests the involvement of the
genes in the module with these molecular pathways.
Recent work in Drosophila strongly reinforces the results
of WGCNA and further suggests a relevant contribution of
KCTD17 to regulation of dopaminergic transmission in the
putamen. Insomniac (the KCTD17 fly ortholog) is an essen-
tial regulator of sleep homeostasis through the control of
the dopaminergic arousal pathways.50,51 More specifically,
insomniac seems to regulate dopaminergic signaling at the
post-synaptic level, possibly controlling the turnover of
dopamine receptors or their downstream effectors.51 Inter-
estingly, abnormal post-synaptic dopaminergic signalingerican Journal of Human Genetics 96, 938–947, June 4, 2015 943
Figure 4. Functional Studies Showing
Abnormalities of Endoplasmic Reticulum
Calcium Signaling in KCTD17 p.(Ar-
g145His) Substitution Bearing Fibroblasts
After obtaining informed consent, fibro-
blasts were isolated from a skin biopsy
taken from a subject with the KCTD17
p.(Arg145His) substitution (index family,
III-2). Two unrelated age- and passage-
matched controls (ctrl 1 and 2) were
selected from in-house cell lines. The fi-
broblasts were cultured in Dulbecco’s
modified Eagle’s medium supplemented
with GlutaMAX, 10% heat-inactivated
fetal bovine serum, and 1% penicillin-
streptomycin. Cytosolic calcium ([Ca2þ]c)
was measured with Fura-2, AM. Fibroblasts
were loaded at room temperature for
30 min with 5M Fura-2 AM and 0.005%
Pluronic in HBSS. Fluorescence measure-
ments were obtained on an epifluores-
cence inverted microscope equipped with
a 203 fluorite objective. [Ca2þ]c wasmoni-
tored in single cells using excitation light
provided by a Xenon arc lamp, with the
beam passing monochromator centered
at 340 and 380 nm (Cairn Research).
Emitted fluorescence light was reflected through a 515 nm long-pass filter to a cooled CCD camera (Retiga, QImaging). All experiments
were carried out in triplicate. Data are represented as the mean 5 SEM ‘‘n’’ indicates the total number of cells analyzed. The asterisks
indicate p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
(A) Typical trace of [Ca2þ]c in control and KCTD17 mutant fibroblasts in response to the application of 50 mM ATP.
(B) Histograms showing a significantly decreased [Ca2þ]c response upon ATP stimulation in mutation-bearing fibroblasts (n ¼ 56) versus
controls (control 1 n ¼ 41; control 2 n ¼ 35), as measured by changes in Fura-2 fluorescence intensity.
(C) Typical trace of [Ca2þ]c in control and KCTD17mutant fibroblasts in response to the application of thapsigargin (1 mM), and subse-
quent Ca2þ challenge (2 mM).
(D) Histograms demonstrating a significant reduction in ER calcium pool in response to thapsigargin in mutation-bearing fibroblasts
(n ¼ 53) versus controls (control 1 n ¼ 51; control 2 n ¼ 65), as measured by changes in Fura-2 fluorescence intensity.in the basal ganglia is one of the main themes in molecular
dystonia pathogenesis, a concept recently strengthened by
the identification of mutations in GNAL causing dysto-
nia.52 Fitting well with this model, all the genes in the
putamen KCTD17module assigned to the KEGG ‘‘dopami-
nergic synapse’’ pathway (CACNA1C [MIM 114205],
PPP1R1B [MIM 604399], PPP2R2C [MIM 605997], AKT1
[MIM 164730], GNAO1 [MIM 139311], and GNB2 [MIM
139390]) localize and act at the post-synaptic level.
Disruption of calcium (Ca2þ) homeostasis has been
recently implicated in the pathogenesis of several genetic
forms of dystonia (e.g., TOR1A, ANO3, HPCA).48,53,54
As the putamen KCTD17-module included HPCA, a
gene with an established role in intracellular Ca2þ-depen-
dent signaling,55 we hypothesized that the KCTD17
p.(Arg145His) substitutionmight have a significant impact
on intracellular Ca2þ homeostasis. For this purpose, fibro-
blasts were isolated from a skin biopsy taken from a subject
with the KCTD17 p.(Arg145His) variant (index family,
III-2). Two unrelated age- and passage-matched controls
were selected from in-house fibroblast lines. The expres-
sion of KCTD17 in fibroblasts was confirmed by RT-PCR
(data not shown). Calcium homeostasis was assessed
using the ratio-metric Ca2þ dye, Fura-2, AM (Molecular
Probes), which indicates intracellular Ca2þ concentration
and allows recordings of Ca2þ fluxes upon application of944 The American Journal of Human Genetics 96, 938–947, June 4, 2different pharmacological stimuli. We observed that stim-
ulation with ATP (50 mM), which stimulates P2Y receptors
and releases Ca2þ from the ER via IP3 receptors, resulted
in significantly reduced and delayed cytosolic Ca2þ
signal (p < 0.01; Figures 4A and 4B) in cells carrying the
p.(Arg145His) mutation when compared to both control
cells, indicating a smaller calcium pool within the ER. To
further prove this finding, we subsequently carried out a
second round of experiments using thapsigargin (1 mM)
in Ca2þ-free medium (plus 0.5 mM EGTA). Thapsigargin
is an inhibitor of the ER calcium ATPase (SERCA) and
induces the release of calcium from the ER to the cytosol,
allowing an estimation of the ER Ca2þ-pool. Ca2þ was
then added at the end of the experiment to stimulate eleva-
tion of cytosolic Ca2þ through opening of store operated
calcium channels. Thapsigargin stimulation resulted in a
significantly smaller Ca2þsignal in fibroblasts bearing the
p.(Arg145His) mutation when compared to controls (p <
0.01; Figures 4C and 4D), confirming that the Ca2þ pool
in the ER of mutation-carrying fibroblasts is reduced.
Furthermore, stimulation of the store-operated Ca2þ chan-
nels induced a smaller Ca2þ influx in mutated fibroblasts
(Figure 4C), possibly suggesting an insufficient Ca2þ influx
across the plasmamembrane in response to the fall in Ca2þ
concentration within the ER lumen. Interestingly, we
recently showed very similar defects of ER Ca2þ storage015
in fibroblasts bearing a pathogenic mutation in ANO3.53
This indicates that defective ER calcium signaling might
represent a converging pathogenic mechanism in geneti-
cally unrelated forms of dystonia.
In conclusion, we demonstrate that a missense mutation
in KCTD17, c.434 G>A p.(Arg145His), represents a rare ge-
netic cause for inherited autosomal dominant M-D.
The clinical features of the KCTD17-mutated cases,
although fully consistent with a clinical diagnosis of
M-D, were distinct in many ways from the usual phe-
notype of subjects with SGCE mutations. Dystonia
dominated the clinical picture and showed a progressive
course, worsening over time and spreading to other sites
(including speech involvement), a course unusual for
SGCE-related M-D. Myoclonus, despite being the present-
ing symptom in most cases, was overall mild and not as
disabling as in SGCE-mutated subjects.
These phenotypic differences might be explained not
only by the different functions of the two genes but also
by the clearly distinct patterns of brain regional expres-
sion. SGCE is highly expressed in the cerebellum, whereas
its expression is low to moderate in putamen and globus
pallidus.56 On the other hand, KCTD17 expression is
high in the putamen and thalamus but relatively low in
the cerebellum. Intriguingly, this could be the explanation
for the scarce response to alcohol consumption in
KCTD17-mutated cases, as alcohol probably exerts its
beneficial effect in M-D secondary to SGCE mutations by
modulating cerebellar activity.56
Preliminary data suggest an involvement of KCTD17 in
dopaminergic signaling and an effect of the p.(Arg145His)
substitution on ER-derived Ca2þ homeostasis. Further
insight into the physiological role of KCTD17 and a
better understanding of the pathogenic effect of the
p.(Arg145His) substitution will shed light onto the mecha-
nisms leading to abnormal neuronal activity underlying
M-D. Furthermore, the identification of KCTD17 interac-
tors will possibly highlight new potential pharmacological
targets for the treatment of dystonia.
Mutational screening of additional cohorts of M-D cases
will help to define the frequency and the spectrum of
KCTD17mutations. KCTD17mutations should be consid-
ered in cases without mutations in SGCE presenting with
myoclonus, dystonia, or a combination of both, particu-
larly if there is predominant cranio-cervical and laryngeal
involvement.Supplemental Data
Supplemental Data include two figures and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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